All In Biotech

Drug Trial Radar · NCT05910827

A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers

A Phase Ib/II Study to Evaluate HMBD-001 in Combination With Cetuximab, With or Without Docetaxel in Participants With Advanced Squamous Cell Carcinomas

Last checked: Nov 20, 2026Latest source record: May 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

398

Planned (sponsor's estimate)

Start

Feb 5, 2024

Primary completion

Dec 1, 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Hummingbird BioscienceIndustry
Sponsor type
Industry
Collaborators
Merck KGaA, Darmstadt, Germany
First posted
Jun 20, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase Ib/II multi-center, open-label study of HMBD-001 in combination with cetuximab with or without docetaxel in participants with advanced Squamous Cell Cancers

Conditions

  • Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
  • Advanced Head and Neck Squamous Cell Carcinoma
  • Advanced Esophageal Squamous Cell Carcinoma
  • Cervical Squamous Cell Carcinoma
  • Advanced Cutaneous Squamous Cell Carcinoma
  • Nasopharyngeal Cancinoma (NPC)
  • Squamous Cell Carcinoma

Interventions

  • HMBD-001Drug

    HMBD-001 is a humanized Immunoglobulin G1 (IgG1) anti-Human Epidermal Growth Factor Receptor 3(HER3) monoclonal antibody (mAb). It is administered intravenously (IV) weekly

  • DocetaxelDrug

    Docetaxel 75 mg/m\^2 or 60 mg/m IV once every 3 weeks

  • CetuximabDrug

    Cetuximab 250 mg/m\^2 weekly, with or without 400 mg/m\^2 IV loading dose at C1D1

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and Nature of Adverse Events (AEs)Time frame: From the time the Informed Consent Form (ICF) is signed until 30 days after last dose of study treatment
  2. Number of participants with dose-limiting toxicities (DLTs) - applicable to part ATime frame: From date of enrollment (first dosing) until the end of Cycle 1 (each cycle is 21 days)
  3. Six months progression-free survival (PFS) - applicable to part BTime frame: From date of enrollment (first dosing) until disease progression or death, assessed up to 6 months

Locations

20 sites in 5 countries. Site status is shown where the registry gives one.

  • GenesisCare North Shore

    Sydney, New South Wales, Australia · Withdrawn

  • Westmead Hospital

    Westmead, New South Wales, Australia · Recruiting

  • ICON Cancer Centre South Brisbane

    Brisbane, Queensland, Australia · Withdrawn

  • Greenslopes Private Hospital

    Greenslopes, Queensland, Australia · Recruiting

  • Southern Oncology Clinical Research Unit

    Adelaide, South Australia, Australia · Recruiting

  • Peninsula & South Eastern Haematology and Oncology Group

    Frankston, Victoria, Australia · Recruiting

  • Cabrini Health

    Malvern, Victoria, Australia · Withdrawn

  • Linear Clinical Research

    Perth, Western Australia, Australia · Recruiting

  • The Institute of Oncology, ARENSIA Exploratory Medicine Phase I Unit

    Chisinau, Moldova · Recruiting

  • National Cancer Centre Singapore

    Singapore, Singapore · Recruiting

  • Tan Tock Seng Hospital

    Singapore, Singapore · Recruiting

  • Chungbuk National University Hospital

    Cheongju-si, South Korea · Recruiting

  • CHA Bundang Medical Center, CHA University

    Seongnam-si, South Korea · Recruiting

  • Korea University Anam Hospital

    Seoul, South Korea · Recruiting

  • Severance Hospital

    Seoul, South Korea · Recruiting

  • The Catholic University of Korea St. Vincent's Hospital

    Suwon, South Korea · Recruiting

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    Kaohsiung City, Taiwan · Recruiting

  • National Cheng Kung University Hospital

    Tainan, Taiwan · Recruiting

  • Taipei Medical University - Shuang Ho Hospital

    Taipei, Taiwan · Recruiting

  • Taipei Veterans General Hospital

    Taipei, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.